Ventilator-induced diaphragm dysfunction. Other complication of respirator [ventilator]
Conditions
Interventions
Intervention 1: Intervention group: For 30 intubated patients and one week after the start of mechanical ventilation, 10 units/kg of the recombinant human peptide growth hormone somatropin (trade name
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Age range 18-60 years Intubated due to severe bacterial pneumonia Inability to weaning
Exclusion criteria
Exclusion criteria: Previous neuromuscular diseases Previous lung disease (obstructive disease, restrictive disease) Chronic heart failure (EF<40) Cancer patients
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Weaning. Timepoint: Once at the beginning of the second week of hospitalization (before the first dose of the drug is injected) and once at the end of the second week (after receiving 7 doses of the drug). Method of measurement: Observation of successful weaning of a patient from the ventilator.;Diaphragm thickness. Timepoint: Once at the beginning of the second week of hospitalization (before the first dose of the drug is injected) and once at the end of the second week (after receiving 7 doses of the drug). Method of measurement: Ultrasound. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMarziye Shahrabi
Shahid Beheshti University of Medical Sciences
Outcome results
None listed